Genmab A/S (NASDAQ:GMAB) Shares Gap Down to $29.43

Genmab A/S (NASDAQ:GMAB - Get Free Report)'s share price gapped down before the market opened on Wednesday . The stock had previously closed at $29.43, but opened at $28.78. Genmab A/S shares last traded at $28.83, with a volume of 30,523 shares trading hands.

Wall Street Analyst Weigh In

GMAB has been the topic of several recent research reports. HC Wainwright restated a "buy" rating and issued a $50.00 price target on shares of Genmab A/S in a research report on Thursday, April 4th. BMO Capital Markets upgraded shares of Genmab A/S from a "market perform" rating to an "outperform" rating and boosted their price objective for the company from $46.00 to $48.00 in a report on Friday, February 23rd. Truist Financial reissued a "buy" rating and issued a $50.00 price target on shares of Genmab A/S in a report on Tuesday, March 26th. Morgan Stanley reissued an "underweight" rating on shares of Genmab A/S in a research note on Tuesday, March 26th. Finally, Citigroup lowered Genmab A/S from a "neutral" rating to a "sell" rating in a research report on Monday, January 22nd. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $48.50.

Genmab A/S Trading Down 3.1 %

The firm's 50 day moving average price is $29.34 and its two-hundred day moving average price is $30.36. The company has a market capitalization of $18.86 billion, a P/E ratio of 29.76, a PEG ratio of 2.12 and a beta of 0.99.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its quarterly earnings data on Wednesday, February 14th. The company reported $0.36 EPS for the quarter, topping analysts' consensus estimates of $0.34 by $0.02. Genmab A/S had a net margin of 26.50% and a return on equity of 18.06%. The company had revenue of $675.29 million during the quarter, compared to the consensus estimate of $678.14 million. Analysts anticipate that Genmab A/S will post 1.06 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Genmab A/S

Institutional investors and hedge funds have recently modified their holdings of the company. First Manhattan Co. bought a new position in shares of Genmab A/S during the 4th quarter worth approximately $26,000. Headlands Technologies LLC bought a new position in shares of Genmab A/S in the third quarter valued at about $27,000. Pinnacle Bancorp Inc. lifted its stake in shares of Genmab A/S by 315.8% during the 4th quarter. Pinnacle Bancorp Inc. now owns 840 shares of the company's stock worth $27,000 after buying an additional 638 shares during the last quarter. GAMMA Investing LLC boosted its holdings in shares of Genmab A/S by 194.0% during the 1st quarter. GAMMA Investing LLC now owns 1,135 shares of the company's stock worth $34,000 after buying an additional 749 shares during the period. Finally, NBC Securities Inc. acquired a new position in Genmab A/S in the 3rd quarter valued at about $37,000. 7.07% of the stock is owned by institutional investors.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.